NUC-3373 for colorectal cancer - Clinical Trial

What is the Purpose of this Study?

If you choose to join this study, you will:
- Get NUC-3373 by IV every 1 or 2 weeks
- Get chemotherapy and/or bevacizumab every 2 weeks
- Give blood and urine samples
- Have regular CT or MRI scans

What is the Condition Being Studied?

Colorectal Cancer

Who Can Participate in the Study?

Adults with colorectal cancer who:
- Have locally advanced, unresectable, or metastatic disease
- Have already received at least 1 line of treatment

For more information about who can join this study, please contact the study team at kelsey.conner@duke.edu.

Age Group
Adults

What is Involved?

We are doing this study to see if the study drug, NUC-3373, is safe and effective for treating colorectal cancer when combined with existing therapies.

Study Details

Full Title
[Nutide302] A Phase Ib/II open label study to assess the safety and pharmacokinetics of NUC-3373, a nucleotide analogue, given in combination with standard agents used in colorectal cancer treatment
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00109258
NCT: NCT03428958
Phase
Phase I/II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698